Incident hepatocellular carcinoma in patients with type 2 diabetes (Comparison between propensity-score matched cohorts)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)		HR (95% CI)
	Overall		(=:4=======	(сетринест сето,		
46,470	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	28 (0.06%)	131 (0.28%)		0.20 (0.14–0.31)
46,260	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	134 (0.29%)	138 (0.30%)	⊢ •	0.99 (0.79–1.27)
102,868	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	253 (0.25%)	262 (0.26%)	- ■ 1	0.89 (0.76–1.05)
53,204	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	160 (0.30%)	148 (0.28%)	⊢	1.03 (0.82–1.29)
93,354	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	223 (0.24%)	269 (0.27%)	⊢■	0.78 (0.65–0.93)
62,618	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	167 (0.27%)	137 (0.22%)	 ■ 	1.15 (0.92–1.45)
	No insulin					
13,344	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	<10 (<0.08%)	14 (0.11%)	- -	0.63 (0.26–1.50)
32,187	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	21 (0.07%)	24 (0.08%)	- ■	0.82 (0.46–1.47)
21,155	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	18 (0.09%)	12 (0.06%)	 	1.45 (0.70–3.01)
28,461	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	15 (0.05%)	38 (0.13%)		0.39 (0.21-0.69)
22,182	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	18 (0.08%)	<10 (<0.05%)		1.72 (0.80–3.73)
					0.20 0.30 0.50 0.70 1.0 2.0 3.00 4.0 Hazard Ratio (HR)	